Home
→
Browsing by Author

Browsing by Author "Negredo, Eugenia"

Now showing items 1-13 of 13

Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients

Echeverria, Patricia; Guardiola, M.; González, Marta; Vallvé, Joan Carles; Bonjoch, Anna; Puig, Jordi; Clotet, Bonaventura; Ribalta, J.; Negredo, Eugenia (Elsevier, 2015)

Several studies have reported associations between lipid parameters and clinical progression of HIV infection. We performed a cross-sectional study including 468 antiretroviral-treated HIV-infected patients to investigate ...
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables

Muñoz-Moreno, José A.; Pérez Alvarez, Núria; Muñoz-Murillo, A.; Prats, A.; Garolera, M.; Jurado, M.A.; Fumaz, C.R.; Negredo, Eugenia; Ferrer, M.J.; Clotet, Bonaventura (Plos One, 2014)

Objective: We used demographic and clinical data to design practical classification models for prediction of neurocognitive impairment (NCI) in people with HIV infection. Methods: The study population comprised 331 ...
Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years

Negredo, Eugenia; Bonjoch, Anna; Pérez Alvarez, Núria; Ornelas, Arelly; Puig, Jordi; Herrero, C.; Estany, Carla; Río, L. del; Gregorio, S. di; Echeverria, Patricia; Clotet, Bonaventura (Blackwell Publishing, 2015)

Objectives Given the need for easily managed treatment of osteoporosis in HIV-infected patients, we evaluated the efficacy and tolerability of two doses of zoledronate, by comparing three groups of patients: those with ...
Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals

Massanella, Marta; Ouchi, Dan; Marfil, Sílvia; Llibre, Josep M.; Puertas, M.C.; Buzon, Maria J.; Richman, Douglas D.; Orna, Elisa; Stevenson, Mario; Gatell, J.M.; Domingo, Pere; Negredo, Eugenia; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Blanco, Julià (Public Library of Science, 2014)

Abstract Background HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART ...
High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors

Bonjoch, Anna; Juega, J.; Puig, Jordi; Pérez Alvarez, Núria; Aiestarán, A.; Echeverria, Patricia; Pérez, V.; Clotet, Bonaventura; Romero-Ortuno, Roman; Bonet, J.; Negredo, Eugenia (Mary Ann Liebert, 2014)

Renal disorders are an emerging problem in HIV-infected patients. We performed a cross-sectional study of the first 1000 HIV-infected patients attended at our HIV unit who agreed to participate. We determined the frequency of ...
Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

Massanella, Marta; Gómez-Mora, Elisabet; Carrillo, Jorge; Curriu, Marta; Ouchi, Dan; Puig, Jordi; Negredo, Eugenia; Cabrera, Cecilia; Clotet, Bonaventura; Blanco, Julià (Biomed central, 2015)

Abstract Background: High levels of ex vivo CD4 T-cell death and the accumulation of highly differentiated and/or immunosenescent T cells have been associated with poor CD4 T-cell recovery in treated HIV-infected ...
Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner

Guardiola, M.; Echeverria, Patricia; González, Marta; Vallvé, Joan Carles; Puig, Jordi; Clotet, Bonaventura; Ribalta, J.; Negredo, Eugenia (Mary Ann Liebert, 2015)

Introduction: HIV-infected patients treated with Highly Active Antiretroviral Therapy (HAART) may be predisposed to hypertriglyceridemia, which gives rise to a highly atherogenic lipid profile known as atherogenic ...
Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

Echeverria, Patricia; Domingo, Pere; Llibre, Josep M.; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Bonjoch, Anna; Pérez Alvarez, Núria; Sirera, Guillem; Clotet, Bonaventura; Negredo, Eugenia (Hindawi Publishing Corporation, 2014)

There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) inHIV-infected patients. Methods.We performed a retrospective descriptive ...
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (International AIDS Society, 2014)

Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It ...
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels

Negredo, Eugenia; Diez-Pérez, Adolfo; Bonjoch, Anna; Domingo, Pere; Pérez Alvarez, Núria; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Echeverria, Patricia; Escrig, R.; Clotet, Bonaventura (Oxford University Press, 2015)

Background: Tenofovir is involved in accelerated bone mineral density (BMD) loss. Methods: We recently published a hip BMD improvement at week 48 [+2.1% (95% CI: 20.6, 4.7) (P¼0.043)] in HIV-infected patients with ...
Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients

Negredo, Eugenia; Puig, Jordi; Ornelas, Arelly; Echeverria, Patricia; Bonjoch, Anna; Estany, Carla; Higueras, Carmen; Gonzalez-Mestre, Vicente; Clotet, Bonaventura (Mary Ann Liebert, 2015)

Long-term results ( > 5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among ...
The Lipid-Lowering Effect of Tenofovir/ Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Llibre, Josep M.; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (Oxford University Press, 2015)

Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral emtricitabine (FTC), has a lipid-lowering effect. Methods. We performed a randomized, crossover, ...
USeminars. L'envelliment amb el VIH: Un procés accentuat i accelerat

Negredo, Eugenia (14-12-2016)

Now showing items 1-13 of 13

Search RIUVic

Browse

All of DSpace

Browsing by Author "Negredo, Eugenia"

Browsing by Author "Negredo, Eugenia"

Search RIUVic

Browse

All of DSpace